Status:
ENROLLING_BY_INVITATION
Pathways of Eicosanoid Metabolism
Lead Sponsor:
Vanderbilt University
Collaborating Sponsors:
Vanderbilt University Medical Center
Conditions:
Metabolism of Prostaglandin D2
Eligibility:
All Genders
18-65 years
Phase:
EARLY_PHASE1
Brief Summary
Prostaglandins are important signaling compounds formed from arachidonic acid. The enzymes that form prostaglandins, cyclooxygenase-1 and -2 are the targets of non-steroidal anti-inflammatory drugs (N...
Detailed Description
The objective of this study is to determine whether PGD2 is metabolized to 11-dehydro-TxB2 in humans. Because the levels of PGD2 and its metabolite, PGD-M, are low in human urine, the investigators wi...
Eligibility Criteria
Inclusion
- Normal, healthy volunteers not currently taking any medication.
Exclusion
- Use of anti-inflammatory/over-the-counter pain medications (NSAIDs) up to 2 weeks prior to study.
Key Trial Info
Start Date :
August 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2026
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04464070
Start Date
August 15 2020
End Date
August 31 2026
Last Update
June 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University
Nashville, Tennessee, United States, 37232